醫藥相關股隨A股受捧 康希諾AH飆20%-22% 騰盛博藥漲13%
上海今天啟動由康希諾-B(06185.HK)生產吸入式新冠疫苗加強接種,或掀起內地新一輪加強針接種熱。此外,美國總統拜登25日接種針對變種病毒Omicron加強針,並警告隨著天氣變冷,美國新冠疫情或將惡化。A股新冠藥物、醫藥生物、病毒防治、生物疫苗、創新藥及醫療美容板塊急漲5.1%-6.7%(跑贏滬指及深成僅回升0.8%-1.7%)。本港相關也受捧,尤其是康希諾午後初段高見65元,現報64.8元,急漲22%,成交增至777萬股;康希諾A(688185.SH)急漲20%漲停報160.76元人民幣。
騰盛博藥(02137.HK)急漲13%曾高見5.98元。金斯瑞生物(01548.HK)、威高股份(01066.HK)、科濟藥業-B(02171.HK)、開拓藥業-B(09939.HK)、歌禮製藥-B(01672.HK)及康龍化成(03759.HK)升逾6%-8%。上海醫藥(02607.HK)及百濟神州(06160.HK)升約4%。諾誠健華-B(09969.HK)續升逾5%曾見9.78元;諾誠A(688428.SH)漲8.6%曾高見13.57元人民幣。
藍籌醫藥股也全面報升,但高位遇壓,尤其是藥明生物(02269.HK)由曾漲8.4%至41.95元,收窄至僅升3%報39.85元;翰森(03692.HK)及石藥(01093.HK)由最高位14.04元及8.79元,回順至14元及8.7元,升逾5%;中生(01177.HK)也曾升逾6%至4.31元,收窄至升2.5%報4.16元。此外,料中績虧轉賺逾八千萬人民幣阿里健康(00241.HK)續彈8%曾高見3.67元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.